| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114
Address all correspondence and requests for reprints to: Karen K. Miller, Neuroendocrine Unit, Bulfinch 457B, Massachusetts General Hospital, Boston, Massachusetts 02114. E-mail: KKMiller{at}partners.org.
Context: Data regarding gender-specific efficacy of GH on critical endpoints are lacking. There are no randomized, placebo-controlled studies of physiological GH therapy solely in women.
Objective: Our objective was to determine the effects of physiological GH replacement on cardiovascular risk markers and body composition in women with GH deficiency (GHD).
Design: This was a 6-month, randomized, placebo-controlled, double-blind study.
Setting: The study was conducted at the General Clinical Research Center.
Study Participants: 43 women with GHD due to hypopituitarism were included in the study.
Intervention: Study participants were randomized to receive GH (goal mid-normal serum IGF-1) or placebo.
Main Outcome Measures: Cardiovascular risk markers, including high-sensitivity C-reactive protein, tissue plasminogen activator, and body composition, including visceral adipose tissue by cross-sectional computed tomography, were measured.
Results: Mean daily GH dose was 0.67 mg. The mean IGF-1 SD score increased from –2.5 ± 0.3 to –1.4 ± 0.9 (GH) (P < 0.0001 vs. placebo). High-sensitivity C-reactive protein decreased by 38.2 ± 9.6% (GH) vs.18.2 ± 6.0% (placebo) (P = 0.03). Tissue plasminogen activator and total cholesterol decreased, and high-density lipoprotein increased. Homeostasis model assessment-insulin resistance and other markers were unchanged. Body fat decreased [–5.1 ± 2.0 (GH) vs. 1.9 ± 1.0% (placebo); P = 0.002] as did visceral adipose tissue [–9.0 ± 5.9 (GH) vs. 4.3 ± 2.7% (placebo); P = 0.03]. Change in IGF-1 level was inversely associated with percent change in visceral adipose tissue (r = –0.61; P = 0.002), total body fat (r = –0.69; P < 0.0001), and high-sensitivity C-reactive protein (r = –0.51; P = 0.003).
Conclusions: Low-dose GH replacement in women with GHD decreased total and visceral adipose tissue and improved cardiovascular markers, with a relatively modest increase in IGF-1 levels and without worsening insulin resistance.
This article has been cited by other articles:
![]() |
M. Russell, M. Bredella, P. Tsai, N. Mendes, K. K. Miller, A. Klibanski, and M. Misra Relative Growth Hormone Deficiency and Cortisol Excess Are Associated with Increased Cardiovascular Risk Markers in Obese Adolescent Girls J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2864 - 2871. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Palmer, M.-Y. Chung, E. O. List, J. Walker, S. Okada, J. J. Kopchick, and D. E. Berryman Age-Related Changes in Body Composition of Bovine Growth Hormone Transgenic Mice Endocrinology, March 1, 2009; 150(3): 1353 - 1360. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Mekala and N. A. Tritos Effects of Recombinant Human Growth Hormone Therapy in Obesity in Adults: A Metaanalysis J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 130 - 137. [Abstract] [Full Text] [PDF] |
||||
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |